Personal Data Protection Policy

In accordance with the Spanish Personal Data Protection Act [Ley Orgánica de Protección de Datos de carácter personal], Pharma Mar hereby informs users of the existence of an automated personal data file created by Pharma Mar, S.A., and under its responsibility for the purpose of maintaining and managing the relationship with parties who request information or users who access this website through electronic forms or by e-mail messages. The abovementioned file has been registered with the Spanish Data Protection Agency in compliance with the regulations currently in force. The data that you provide to Pharma Mar will be used to manage your request, provide you with the information and/or services you request, and offer you new services.

Pharma Mar maintains secure levels of protection of its data in accordance with current regulations and has taken all measures technically available to it to prevent the loss, misuse, alteration, unauthorized access and theft of the data that you provide through the website.

By sending data through the use of the electronic forms on this website or e-mail messages, the sender is agreeing to automated processing of the data included in the media indicated. The data will not be disclosed to third parties. The user warrants that the personal data provided to Pharma Mar are accurate and agrees to notify Pharma Mar of any changes in such data.

Users may exercise their rights to access, rectify, cancel and oppose such data on record under the terms established in the Spanish Data Protection Act and the regulations implementing such act, by sending a written notice to the Legal Department of Pharma Mar S.A., at Avda. de los Reyes nº 1, Pol. Ind. La Mina, 28770 Colmenar Viejo (Madrid), Spain.

Science & Innovation

Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom